Haemorrhoids is a common anorectal condition affecting millions worldwide. We have studied the effect of endothelin-1 (ET-1) and the role of endothelin ET A and ET B receptors in haemorrhoid tissue.
Introduction
Haemorrhoids is a common anorectal condition defined as the symptomatic enlargement and distal displacement of the normal anal cushion that affects millions worldwide and represents a major medical and socio-economic problem (Loder et al., 1994; Lohsiriwat, 2012; Jacobs, 2014) . The prevalence of haemorrhoids has been reported to be as high as 30-39% in the adult general population, (Loder et al., 1994; Acheson and Scholefield, 2008) with the most common symptom being rectal bleeding upon bowel movement. Pain is a symptom generally associated with advanced internal haemorrhoids, once they become strangulated or exhibit signs of thrombosis, and can occur with external haemorrhoids (Kaidar-Person et al., 2007; Acheson and Scholefield, 2008) . Surgical approaches are often used for the worst grades of haemorrhoids, but are generally avoided because of the potential for severe postoperative pain and long-term complications (Kaidar-Person et al., 2007; Acheson and Scholefield, 2008) with pharmacological intervention preferred instead (Acheson and Scholefield, 2008) .
A characteristic feature of haemorrhoids is abnormal venodilatation together with destructive changes in the supporting connective tissue within the anal cushion (Loder et al., 1994; Lohsiriwat, 2012) . Furthermore, there is evidence of dysregulation of vascular tone and vascular hyperplasia associated with the enlargement and development of haemorrhoidal tissues (Loder et al., 1994; Lohsiriwat, 2012) . For example, Aigner and colleagues (Aigner et al., 2006) have reported that blood flow in the terminal branches of the superior rectal artery of patients with haemorrhoids is two to threefold greater than that found in healthy subjects. Moreover, these changes correlated with the calibre of the vessel and the Goligher's grade of internal haemorrhoids. It is well established that the arterial supply and venous drainage of the anal cushions and haemorrhoids are part of the splanchnic (mesenteric) circulation and haemorrhoidal arteries connect to an extensive arteriovenous plexus within the anorectal submucosa without a capillary bed (Aigner et al., 2009) . However, microcasts of haemorrhoidal tissue have revealed that the capacitance side of the arteriovenous plexus accounts for practically the whole volume of this vascular bed (Aigner et al., 2009 ).
The existing creams used to treat the symptoms of haemorrhoids generally consist of an anti-inflammatory glucocorticoid, an 'astringent' claimed to influence vascular permeability, a local anaesthetic and, in some instances, a vasoconstrictor to limit blood flow ( (Acheson and Scholefield, 2008; Lohsiriwat, 2012) . In the case of Preparation H®, for example, phenylephrine is incorporated as a vasoconstrictor agent and is generally known to exert a preferential effect on the arterial side of the circulation (Lohsiriwat et al., 2011) .
As far as we are aware, there is little information regarding the distribution and function of receptors on the arterial and venous side of anal cushions and their role in controlling overall tissue volume. Part of the problem may relate to the difficulty in studying small calibre blood vessels in haemorrhoidal tissue in vitro. In a recent study, however, we demonstrated that vasoconstrictor endothelin ET A and ET B receptors are present on sheep rectal arteries and veins (vessels that supply and drain anal cushions) with the latter selectively activated by the snake venom peptide sarafotoxin S6a (Lohsiriwat et al., 2011) . Endothelin-1 (ET-1) is the most potent vasoconstrictor currently known acting via the two distinct ET A and ET B receptors (Barton and Yanagisawa, 2008) . Although the endothelium is a major source of ET-1, other cells are capable of generating the peptide such as macrophages, vascular smooth muscle and myocardial cells (Masaki, 1993; Luscher and Barton, 2000; Fagan et al., 2001) . The vasoconstrictor action of ET-1 involves both ET A and ET B receptors located on vascular smooth muscle and ET-1-mediated vasodilatation via endothelial ET B receptors. While no selective ET A receptor agonists are currently available, sarafotoxin S6a and S6c are peptide-based toxins from Atractaspis engaddensis (McMahon et al., 1991; Minkes et al., 1992; Alexander et al., 2015) that are thought to preferentially activate ET B receptors
In this study we have (i) determined the density and distribution of ET-1, ET A and ET B receptor binding sites in haemorrhoidal tissue using in vitro receptor autoradiography and immunohistochemistry; (ii) compared the level of protein expression of ET A and ET B receptors in haemorrhoids and normal rectal submucosa using Western blot analysis; and (iv) using wire myography, pharmacologically examined the receptors activated by ET-1 and sarafotoxin S6a in segments of human colonic and rectal arteries and veins. 
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Methods
Tissue preparation
Autoradiography of ET-1 and its receptors
The autoradiography protocol used for ET-1 and ET A /ET B receptor binding was that previously described (Dashwood et al., 1993; Ali et al., 2000; Tsui et al., 2004; Hoosein et al., 2007) . scales were prepared using serial dilutions of radioligand that were spotted onto filter paper and attached to microscope slides that were co-exposed to radiation-sensitive film along with the slide-mounted sections.
'Low-resolution' autoradiography. After incubation, slidemounted sections were placed in X-ray cassettes, exposed to Hyperfilm ™ MP (GE Healthcare, UK) for 14 days and then processed according to the manufacturer's instructions. Densitometric analysis of autoradiographs was performed using a Biospectrum AC Imaging System (Ultraviolet Products, Cambridge, UK) and presented as radioactivity mm À2 tissue (dpm × 10 3 mm À2 ) as previously described (Ali et al., 2000; Tsui et al., 2004; Hoosein et al., 2007) . Specific binding was determined by subtracting NSB from total binding.
'High-resolution' autoradiography. After exposure to film, selected slide-mounted sections were dipped in molten K2 emulsion (Ilford, UK) for microscopic localization of radioligand binding. Emulsion was processed according to the manufacturer's instructions and sections stained with haematoxylin and eosin for histological examination as previously described (Ali et al., 2000; Hoosein et al., 2007) . Autoradiographs were viewed under dark-field illumination and stained tissue under bright-field illumination.
Immunohistochemistry
Standard immunohistochemistry was performed on slidemounted tissue sections (from 14 haemorrhoids and 6 rectal samples) using the Avidin-Biotin Complex Alkaline Phosphatase method (ABC-Alkaline Phosphase kit, Vector Laboratories Inc, USA) following the manufacturer's instructions. Vector® red substrate was used as the chromogen, and sections were counterstained with Haematoxylin. The following antibodies were used: mouse anti-human monoclonal antibody against endothelial cells (CD31, clone JC70A, 1:100, DakoCytomation, Denmark); rabbit anti-human monoclonal antibodies against ET A and ET B receptor (both 1:200, Alomone Labs, Israel), mouse anti-human monoclonal antibody against smooth muscle actin (clone 1A4, 1:200, DakoCytomation, Denmark).
Western blotting
Standard Western blot analysis was used. De-epithelialised haemorrhoid specimens (n = 13) and rectal submucosal tissue (n = 6), where the arteriovenous plexus is located, was used to prepare protein samples. Sample mixtures were loaded onto the SDS-PAGE and human microvascular endothelial cell solution was used as a positive control. Proteins in the gel were transferred to a nitrocellulose membrane (Hybond ECL, Amersham, UK), and 5% powdered milk in PBS-Tween solution was used to block non-specific protein binding. Membranes were incubated with primary antibody at a suitable dilution and, as a loading control, the membrane was also subjected to a mouse monoclonal IgG to GAPDH (1:5000, Santa Cruz Biotechnology Inc, USA). Membranes were then processed with ECL ™ Western Blot detection reagent and film was developed using Hyperfilm ECL (both
Figure 1
Under light microscopy, haematoxylin and eosin-stained sagittal sections of haemorrhoids showed marked dilatation of vascular spaces, particularly venous channels, together with a loose and fragmented connective tissue stroma. Scale bar = 5 mm.
GE Healthcare, UK), and bands were analysed and quantified densitometrically using Biospectrum AC Imaging System (Ultraviolet Products, Cambridge, UK Russell and Davenport, 1996) , or a combination of the two antagonists. The maximum contraction produced by the third exposure to 60 mM KCl was used as a reference contraction for all subsequent responses. ET-1 and sarafotoxin S6a were the endothelin receptor agonists used and in some experiments responses were compared to those elicited by noradrenaline.
Data and statistical analysis
The data and statistical analysis in this study comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . The level of expression of each protein was reported as a percentage of the GAPDH protein level. Results are expressed as mean ± SEM of n observations, where n is the number of tissues from different patients. In the wire myograph studies, a curve-fitting programme (KaleidaGraph, Synergy Software, Reading, PA) was used to construct a CRC that had the best fit to a series of data points, and to determine maximum responses (E max ) and agonist potency (pEC 50 : the negative logarithm of the concentration required to produce 50% of the maximum response). The E max values are expressed as a percentage of the third 60 mM KCl response. Results are expressed as mean ± SEM of n observations, where n is the number of studies in tissue from different patients. The logarithm of dissociation constant of the antagonist (pK B ) was estimated based on the agonist concentration ratio (CR) in the presence and absence of the antagonist using the equation pK B = log [Antagonist] À log (CR-1). All data were prepared and compiled using the SPSS® software (version 15.0 for Windows, Illinois, USA). The Kolmogorov-Smirnov test was used to test for the pattern of data distribution. Unpaired or paired Student's t-test was used to compare data between two groups when the data were in a normal distribution pattern. The Mann-Whitney U-test or Wilcoxon Signed Rank test was used to compare data between two groups when the data were in a non-normal distribution. If there were more than two groups being analysed, the ANOVA with an appropriate post hoc test would be used. A P-value <0.05 was considered statistically significant.
Materials
The drugs used were: PD 156707 (sodium 2-benzo(1,3ioxol-5-yl-4-(4-methoxy-pheny l)-4-oxo-3-(3,4,5-trimethoxyben-
ET-1, sarafotoxin S6a (Tocris Bioscience, UK) and noradrenaline bitartrate Endothelin-1 and its receptors on haemorrhoids BJP (Sigma-Aldrich, UK). All drugs used were of analytical grade. PD156707 and BQ788 were dissolved in DMSO (Sigma-Aldrich, UK). ET-1 and sarafotoxin S6a were prepared in distilled water. Noradrenaline was dissolved in aqueous solution containing 20 μM EDTA. The drug concentrations reported are the final concentrations in the organ bath solution.
Results
Patient demographics
The mean age (range) of patients with haemorrhoids and those with rectal cancer was 59 (46-76), and 69 (57-79) respectively. Male patients accounted for 57% of the haemorrhoid group and 67% of the rectal cancer group. There Figure 6 Positive immunoreactivity of ET A receptors (left) and ET B receptors (middle) in venous sinusoids from haemorrhoids at high magnification: positive immunostaining is red. There is stronger vascular smooth muscle staining for ET B than for ET A receptors. The control slide (Neg, right) showed no evidence of positive staining. The horizontal scale bar represents 25 μm. 
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was no significant difference in age and gender between the two groups. Of 14 haemorrhoid specimens, 12 (86%) were grade III and two (14%) were grade IV haemorrhoids.
Endothelin receptor binding sites and Western blots
There was dense [ 125 I]-ET-1 binding to various areas of haemorrhoidal specimens, including both vascular channels and interstitial tissue (Figure 2A ). NSB was low and accounted for 10-15% of total binding with a higher degree of binding mainly located in the mucosa and the area of vascular thrombosis which was evident in the right lower quadrant of Figure 2B . Figure 2D ) was higher than that of ET A receptor binding ( Figure 2C ) (12.7 ± 3.0 vs. 4.4 ± 2.0 dpm × 10 3 mm -2 ), this did not attain statistical significance (P > 0.05, n = 3).
Protein expression of ET A and ET B receptors in de-epithelialised haemorrhoid specimens (n = 13) and submucosal tissue of the distal rectum (n = 6) was confirmed by Western blot analysis ( Figure 3A) . In general, haemorrhoids had a non-significant higher protein expression of both ET A and ET B receptors compared to the underlying rectal tissue ( Figure 3B ). Moreover, in haemorrhoidal tissue, the protein level of ET B receptors was significantly threefold higher than that of ET A receptors (P < 0.05). Rectal submucosa also had about four times higher protein expression of ET B receptors than ET A receptors (P < 0.05)
Immunohistochemistry revealed the wall of dilated veins that contained barely any vascular smooth muscle, while the endothelium was relatively well preserved. Nerve fibres, subepithelial smooth muscle (so called Trietz's muscle or the mucosal suspensory ligament) and other fibro-elastic tissues were located between dilated vascular spaces (not shown).
With high-resolution autoradiography, the degree of NSB for 
Figure 7
Representative traces of the contractile response to ET-1 and sarafotoxin S6a in the human isolated mesenteric artery (A,C) and vein (B,D). Increments of two and fivefold agonist concentration were conducted but only log increments (10-fold) are labelled.
Endothelin-1 and its receptors on haemorrhoids BJP
Immunhistochemical studies revealed the presence of ET A ( Figure 5 (lower right) also shows the presence of nerves, as determined by NF200 staining. Figure 6 shows greater immunohistochemical staining for ET B (right) and ET A (left) receptors in venous sinusoids at high magnification. ET B receptor immunoreactivity was also observed in all rectal tissues (6/6; not shown).
Wire myography
Exposure to 60 mM KCl caused a contraction of both HMA and HMV. The mean contraction to 60 mM KCl in the HMA was 3.78 ± 0.21 g wt (n = 29), and that in the HMV was 1.10 ± 0.08 g wt (n = 39). In preliminarily experiments, we tested the viability of the vascular endothelium in three HMA after storage for 8-10 h, by exposing them to the endothelium-dependent vasodilators acetylcholine (1 μM) and bradykinin (100 nM) after contraction with ET-1 (approximately 60% of response to 60 mM KCl) and found that the maximum relaxations were greater than 40 and 80% of constrictor tone respectively.
Noradrenaline (data not shown) and ET-1 ( Figure 7A ,B) caused sustained, concentration-dependent contractions in both blood vessels, with similar maximum contractions, relative to the responses to 60 mM KCl (80 to 130%). However, ET-1 was approximately 100-fold more potent than noradrenaline in the HMA (pEC 50 8.50 ± 0.12, n = 5 compared to pEC 50 6.21 ± 0.08, n = 5) and HMV (pEC 50 8.40 ± 0.17, n = 5 compared to pEC 50 6.18 ± 0.21, n = 5). As shown in Figure 7C ,D, sarafotoxin S6a also elicited concentration-dependent contractions in the HMA and HMV, but was markedly less potent and efficacious than ET-1 in the HMA with only concentrations greater than 0.1 μM eliciting a response ( Figure 8A ). As shown in Figure 7D , in some preparations, a biphasic CRC to sarafotoxin S6a could be observed, with contractions equivalent to 20% of maximum response elicited with concentrations as low as 1 nM. Although the maximum response to sarafotoxin S6a was comparable to that of ET-1 in HMV (Figure 8B ), the potency of sarafotoxin S6a was approximately 1/5th of that of ET-1.
Contractions of the HMA and HMV to ET-1 were displaced in a parallel manner by the selective ET A receptor antagonist 0.1 μM PD 156707 (Table 1) , with an estimated pK B of 7.89 ± 0.26 (n = 4) and 7.37 ± 0.27 (n = 6) respectively. The presence of the selective ET B receptor antagonist BQ788 (0.1 μM) failed to affect responses to ET-1 in the HMA and HMV, either in the presence or absence of 0.1 μM PD 156707 (Table 1 ). In contrast, 0.1 μM BQ788 caused a non-parallel rightward shift of the CRC to sarafotoxin S6a in the HMV ( Figure 8C) , with the lower part of the CRC more affected by the antagonist. The pEC 50 value of sarafotoxin S6a in the absence of BQ788 was 7.68 ± 0.08 (n = 6) whereas that in the presence of 0.1 μM BQ788 was 7.20 ± 0.07 (n = 6). The estimated pK B for BQ788 sarafotoxin S6a was 7.30 ± 0.07 (n = 6).
Discussion and conclusions
Endothelin-1 and endothelin receptors low-resolution autoradiography and the use of selective antagonists for endothelin receptors, the density of ET B receptor binding was generally higher than that of ET A receptor binding, but was variable and the near threefold mean difference did not reach statistical significance. This trend was largely confirmed by Western blotting studies on haemorrhoidal tissue that also revealed the level of ET B receptor protein significantly threefold higher than that of the ET A receptor protein. These novel findings are consistent with the known distribution of endothelin receptors on large blood vessels in the rest of the circulation (Masaki, 1993; Luscher and Barton, 2000) . Positive immunostaining of ET B receptors was uniformly observed in blood vessels of all haemorrhoidal and rectal tissues. Apart from an association with smooth muscle actinstaining, ET B receptor immunoreactivity was also localized to the endothelium. These studies also revealed observations consistent with the report indicating that the arteriovenous plexus comprise large venous sinusoids located alongside small supply arteries (Aigner et al., 2009 ). High-resolution autoradiographic studies provided further insight into the distribution of [
125 I]-ET-1 binding sites in haemorrhoids, which is largely similar to that described by Egidy and colleagues (Egidy et al., 2000) for normal human colon. In submucosal tissue, [ 125 I]-ET-1 bound to both vascular structures (endothelium and smooth muscle cells) as well as to non-vascular structures, including neurons, ganglion cells, myofibroblasts, macrophages and crypt epithelial cells. It should be noted, however, that these studies also revealed areas of the sections where ET A and ET B receptor binding sites in the intravascular region occur at similar density. As the endothelin system is an important regulator of angiogenesis and blood perfusion, any change in ET-1, or receptor expression, could be associated with vascular hyperplasia and high blood flow in haemorrhoids (Loder et al., 1994) . It is conceivable that mechanical injury to the endothelium, caused by shearing forces during defaecation, could increase ET-1 secretion, but it would be necessary to compare ET-1 levels in normal anal cushions with haemorrhoidal tissues. If this is the case, the available evidence suggests that ET A receptors, rather than ET B receptors, are likely to be involved in any endothelin-mediated hyperplasia (Ali et al., 2000; Maguire et al., 2002; Kitada et al., 2009 ).
The effect of endothelin receptor agonists and antagonists on the HMA and HMV Blood supply to the arteriovenous plexus of haemorrhoidal tissue is provided by the rectal (mesenteric) artery and drains into the rectal (mesenteric) vein. As it is not possible at the moment to directly determine the effect of ET-1 on haemorrhoidal vessels, we examined the effect of the peptide on the connecting arteries and veins. In the present study, ET-1 elicited large contractile responses in both the HMA and HMV but (relative to the response to KCl) with a slightly higher maximal response in the vein. The potency of ET-1 was approximately 100-fold greater than noradrenaline, which is consistent with that observed in numerous other human blood vessels. Pharmacological examination of the responses to ET-1 using selective receptor antagonists revealed the involvement of ET A receptors in both preparations. Although the pK B for PD 165707 (7.3-7.7) is lower than that reported for the interaction at ET A receptors (Maguire et al., 1997) , the selective ET B receptor antagonist BQ 788 failed to modify responses either in the absence or presence of PD 165707. These observations with ET-1 in the mesenteric arteries are also consistent with similar observations in both sheep and man (Ferrero et al., 2008; Lohsiriwat et al., 2011) .
The selective ET B receptor agonist sarafotoxin S6a (McMahon et al., 1991; Minkes et al., 1992) was more potent in the vein than in the artery, with an almost fourfold greater maximum response in the former. In some venous preparations, responses to sarafotoxin 6a was observed at concentrations as low as 1 nM (100-fold lower than that seen in arterial preparations) and there was a biphasic concentration response relationship in terms of contractile response. Interestingly, the selective ET B receptor antagonist BQ788 inhibited sarafotoxin S6a-induced contractions in the HMV, with an estimated pK B of 7.3, close to that reported for ET B receptors (Russell and Davenport, 1996) . However, this effect of BQ-788 was associated with a change in the slope of the CRC (steepening) to sarafotoxin 6a, suggesting that both ET A and ET B receptors are activated by the toxin in this vessel, albeit at different concentrations. Although ET B receptors are present on the endothelium and mediate vasodilatation, those on vascular smooth muscle produces vasoconstriction. In the present study, only contractile responses were observed when the vessels were activated by ET-1 and sarafotoxin S6a. A similar finding has been reported in several studies of Endothelin-1 and its receptors on haemorrhoids BJP endothelium-intact human vessels including the internal mammary artery and vein (Seo et al., 1994) , pulmonary artery (McCulloch et al., 1996) , coronary artery (Holm and FrancoCereceda, 1996) , umbilical vein (Mildenberger et al., 2008) and saphenous vein (White et al., 1994) . Interestingly, sarafotoxin S6a has been reported to possess similar pharmacological properties to sarafotoxin S6c (McMahon et al., 1991) , a snake toxin that has been evaluated in man. Sarafotoxin S6c infused intra-arterially in healthy volunteers (5-10 pmol·min À1 for up to 90 min) is known to cause a sustained reduction in forearm blood flow without any systemic side effects (Ferro et al., 2002) . Similarly, intravenous infusion of sarafotoxin S6c caused a sustained reduction in dorsal hand vein blood flow (Strachan et al., 2000) . As sarafotoxin S6a exerts a venoselective constrictor action, the possibility exists that a similar action on the arteriovenous plexus of haemorrhoids could pharmacologically reduce the volume of the tissue, the likelihood of prolapse and also control rectal bleeding. While pain is another key symptom of haemorrhoids (Loder et al., 1994; Kaidar-Person et al., 2007; Lohsiriwat, 2012) and local application of ET-1 is known to induce nociception in rats (Piovezan et al., 2000) , it is noteworthy that this action does not appear to involve ET B receptors. Thus, sarafotoxin S6a could offer a distinct advantage over existing treatments that incorporate a vasoconstrictor agent (e.g. phenylephrine) that appears to selectively target the arterial (in flow) side of the vascular bed. An important step in verifying whether this is true for sarafotoxin 6a would be to establish whether it is possible to adapt for haemorrhoidal tissue (obtained from haemorroidectomies) the tissue slice technique (Sanderson, 2011) developed for simultaneously viewing changes in small arteries and veins in situ in lung slices. This approach has successfully been used to demonstrate that selective α 2 -adrenoceptor agonists with decongestant activity can reduce the volume of venous sinusoids in slices of porcine nasal mucosa, without affecting arterial diameter in the same preparation (see Corboz et al., 2008) . The idea of using a snake toxin, or analogues, to possibly alleviate the vascular symptoms associated with haemorrhoids clearly represents an unconventional approach and is not without major toxicological considerations and the need to develop a suitable formulation. It should be noted, however, that botulinum toxin, from the microorganism Clostridium botulinum, is currently used in an injectable form to treat anal fissures (Nelson et al., 2012) and toxins in general represent a rich area of therapeutic possibilities (Lewis and Garcia, 2003) . However, before considering the use of sarafotoxins as a novel therapeutic strategy for haemorrhoids, it will be necessary to establish whether the functional properties of ET A and ET B receptors within the haemorrhoidal vascular-plexus are similar to those noted in colonic and rectal vessels in this study and other human tissue (Maguire et al., 2012) .
In conclusion, we have established that the ET B receptors are present on haemorrhoids at greater density than ET A receptors, yet the latter is the principal receptor activated by ET-1 to induce contraction of human mesenteric arteries and veins. In contrast, the snake toxin sarafotoxin S6a exerts a selective venoconstrictor effect involving ET B receptors. The latter finding raises the intriguing possibility that topical application of sarafotoxin S6a may be useful to reduce both bleeding and swelling associated with low grade haemorrhoids.
